23 results about "Cellular Assay" patented technology

In the field of cell-based assays, i.e. cellular assays, there is a need for improved cell culture retaining inserts and cell culture retaining insert assemblies. A cell culture retaining insert (10; 70; 90; 100), for retaining a three-dimensional biological sample in a cell culture vessel (102; 132), comprises an insert body (12; 104) that has a positioning formation (16) to in-use locate the cell culture retaining insert (10; 70; 90; 100) relative to a cell culture vessel (102; 132). The insert body (12; 104) also has a retention element receiving formation (20). The cell culture retaining insert (10; 70; 90; 100) additionally includes a retention element (30; 60; 72; 92; 114) which is movably coupled with the receiving formation (20) of the insert body (12;104), whereby a distal retention end (32) of the retention element (30; 60; 72; 92; 114) is freely movable away from and towards the insert body (12; 104), and whereby in-use the weight of the retention element (30; 60; 72; 92; 114) less a buoyant force equal to the weight of any fluid the retention element (30; 60; 72; 92; 114) displaces gives rise to the retention end (32) exerting a retention force on one or more said biological samples.

The invention provides a pharmaceutical composition for treating prostatitis and a preparation method thereof. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 20 to 60 parts of palmatine, 20 to 60 parts of paeoniflorin, 10 to 30 parts of formononetin, 20 to 60 parts of astilbin and 10 to 40 parts of stigmasterol. In-vitro cell tests and in-vivo animal experiments prove that the pharmaceutical composition has the effect of relieving the chronic prostatitis reaction.

The application provides a cell detection plate and belongs to the technical field of cell detection. The cell detection plate comprises a detection plate body, and a tilting mechanism for driving the detection plate to tilt is arranged below the detection plate body. The supernatant extracted from a cell culture tank can be conveyed to the inside of the third tower head through a pipeline, the second tower head is communicated with a diluent through a pipeline, the diluent flows into the second flow channel, the supernatant flows into the third flow channel, and then flows into the inside of the first tower head from the first flow channel after passing through the detection area. Through the arrangement of multiple groups of converging points, the supernatant and the diluent can be fully mixed and uniformly mixed, so that the cells in the inside of the detection plate body can be detected, thereby solving the problem that the cells may be contaminated when the cells are exposed to air during the transfer process during cell detection.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

The application discloses a non-natural sugar and a synthesis method and application thereof. At room temperature, hydroxyl groups of an amino sugar are fully trimethylsilyl-protected, amino groups on the sugar are selectively exposed, and after coupling and conversion of the amino groups at room temperature, a non-natural sugar with orthogonal groups and full trimethylsilyl protection is obtained. The non-natural sugar with orthogonal groups and full trimethylsilyl protection is removed from trimethylsilyl protection groups, and a non-natural sugar without protection groups is obtained. The application takes into account the advantages of existing non-natural sugars, ensures that the non-natural sugars can be efficiently utilized by cells, effectively avoids S side reactions with cysteine in proteins in the metabolic process of the non-natural sugars, and simultaneously realizes efficient metabolic labeling. In a cell test, the use concentration of 1,6-bisacylated non-natural sugar is one order of magnitude lower than that of non-natural sugar without protection groups.

This invention discloses an active peptide from sturgeon cartilage that promotes height growth and improves bone development, along with its preparation method and applications, belonging to the field of active peptide technology. Using sturgeon cartilage as raw material, this invention selects the polypeptide with the highest activity in promoting bone growth and development from different enzymatic hydrolysis combinations through MC3T3-E1 cell experiments, and verifies its positive effect using zebrafish experiments. Subsequently, two potential active peptide sequences from sturgeon cartilage with bone growth and development promotion functions are screened using mass spectrometry to identify their sequences and bioinformatics techniques such as molecular docking. The amino acid sequences of the active peptide segments are shown in SEQ ID NO.2 and SEQ ID NO.5. The sturgeon cartilage peptides prepared by this invention have activity in promoting bone growth and development, which can solve the problem of high-value utilization of sturgeon and can also be used as a functional factor in functional products, showing good application prospects.

The present application provides a use of a compound of formula (I) or a salt thereof in the manufacture of a medicament for the prevention or treatment of diabetes. In particular, a use of a compound of formula (Ia) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of type 1 diabetes. The compounds of the present application have shown efficacy in in vitro cell assays and in a mouse model of type 1 diabetes, and have shown lower side effects in toxicology experiments.

The utility model provides an automatic counting device for cell colonies under a microscope, which comprises a display mirror bracket and a counting camera barrel, an observation mirror is arranged at the lower end of the counting camera barrel, an induction barrel is arranged at the outer end of the counting camera barrel, an induction plate is arranged at the outer end of the induction barrel, the induction plate is attached to the inner surface of the display mirror bracket, and the outer end of the display mirror bracket is connected with a data transmission wire harness. A movable plate and a positioning plate are arranged at the lower end of the display mirror frame, an opening is formed in the outer end of the movable plate, sealing rings are arranged at the inner ends of the movable plate and the positioning plate, a linkage shaft is arranged at the inner end of the opening, a linkage bevel gear is connected to one end of the linkage shaft, a rotating bevel gear is meshed with the outer end of the linkage bevel gear, and a hexagonal rod is arranged at the outer end of the rotating bevel gear; a hexagonal cylinder is arranged at the outer end of the hexagonal rod, and an elastic cylinder is arranged at the inner end of the hexagonal cylinder. The problems that the number of cell colonies cannot be monitored according to time intervals in the design of cell test counting, and an automatic counting device cannot adapt to microscopes of different models are solved.

The present disclosure relates to in vitro cell-based methods that can be used to predict in vivo pharmacokinetic characteristics of candidate therapeutic proteins. In particular, the cell-based assays described herein can be used to predict in vivo non-target dependent clearance and subcutaneous bioavailability of candidate therapeutic proteins.

This invention discloses a sturgeon tendon active peptide that promotes male reproductive function development, its preparation method, and its application, belonging to the field of active peptide technology. The sturgeon tendon active peptide contains at least one of ADLF, FGAGGFA, GPGPTP, GPDGY, LEGF, QPGSL, AAFGAA, GEPGL, AGPPVGQP, QLGL, or SPSL. Using sturgeon tendon as raw material, this invention selects the polypeptide with the highest activity in promoting male reproductive function development from different enzymatic hydrolysis combinations through cell experiments. Sequence identification by mass spectrometry and bioinformatics techniques such as molecular docking are used to screen for potential sturgeon tendon active peptides that promote male reproductive function development. The sturgeon tendon active peptide of this invention can solve the problem of high-value utilization of sturgeon and can also be used as a functional factor in functional products, showing good application prospects.

This invention belongs to the field of pharmaceutical technology, specifically concerning novel oxidized isoapofenzyme alkaloids from *Ipomoea aquatica*, their extraction and separation methods, and their applications. The structural formula of the oxidized isoapofenzyme alkaloids is selected from one of the following formulas: In this invention, dried rhizomes of *Ipomoea aquatica* are pulverized, extracted with ethanol under reflux, and the extract is concentrated to obtain an extract. The extract is then subjected to a series of chromatographic analyses and gradient elutions using an acid-soluble, alkali-precipitated, and organic extraction process to obtain compounds 1-3. In vitro cell experiments show that compounds 1-3 can significantly inhibit LPS-induced NO release from RAW264.7, exhibiting anti-inflammatory medicinal properties and broad application prospects in the anti-inflammatory field.

The application belongs to the technical field of molecules, and specifically discloses a pig RPL11 gene promoter and application thereof. RPL11 The nucleotide sequence of the gene promoter is shown as SEQ ID No. 1. The application determines that the promoter can drive the high-efficiency, stable and extensive expression of an exogenous gene in pig tissue cells through a cell test, avoids the problems of gene silencing, inconsistent expression and low expression efficiency of an exogenous promoter possibly occurring in the preparation process of a transgenic pig product, and has practical application value.

The application belongs to the technical field of bacterial liquid cleaning, and particularly relates to a bacterial liquid cleaning device and method for bacterial or cell samples. The device comprises a cleaning well plate, a liquid adding assembly, a liquid sucking assembly, and the bacterial liquid is negatively charged. The liquid adding assembly comprises a liquid adding upper valve block, the liquid adding upper valve block comprises a liquid storage assembly one, and the liquid storage assembly one is connected to a liquid adding assembly one through a liquid adding flow channel. The liquid sucking assembly comprises a liquid sucking upper valve block, the liquid sucking upper valve block is connected to a liquid sucking lower valve block, the liquid sucking lower valve block comprises a liquid storage assembly two, and the liquid storage assembly two is connected to a liquid adding assembly two through a liquid discharging flow channel. The cleaning method comprises the following steps: adding the bacterial liquid into the concave cavity body; adding the cleaning liquid through the liquid adding assembly; sucking the waste liquid through the liquid sucking assembly after the bacterial liquid is cleaned; repeating the cleaning and sucking to obtain the cleaned bacterial liquid; and performing the evaporation drying treatment on the cleaning well plate containing the cleaned bacterial liquid, so as to be transferred to a detection area for cell test detection. The bacterial liquid cleaning device has high efficiency and can improve the accuracy of the cell test.

The present disclosure generally provides methods for identifying olfactory receptor ligand that are more or less likely to be susceptible to olfactory adaptation, and the cellular assays related to identifying such ligands. In some embodiments, the ligand is an olfactory receptor agonist, and, in other embodiments, the ligand is an olfactory receptor antagonist. In some embodiments, the methods comprise identifying which agonists are more susceptible or less susceptible to olfactory adaptation based on one or more kinetic parameters determined from measuring the intracellular concentration of cAMP over time.

The present disclosure generally provides methods for identifying olfactory receptor ligands that are more or less likely to be susceptible to olfactory adaptation, and the cellular assays related to identifying such ligands. In certain embodiments, the methods comprise determining a degree to which certain receptors are internalized by a cell following contact with a receptor ligand. In some embodiments, the methods comprise identifying which ligands are more susceptible or less susceptible to olfactory adaptation based on the determined degree of internalization.

This invention discloses a hexapeptide LR6 with anti-inflammatory activity, its preparation method, and its applications, belonging to the field of small molecule peptide technology. The amino acid sequence of the hexapeptide LR6 is LDAVDR, and it can be prepared by solid-phase synthesis and enzymatic hydrolysis. The hexapeptide LR6 was identified from the protein hydrolysate of *Spirulina platensis* and has a potential interaction with Keap1. LPS-induced RAW264.7 cell assays showed that both low-dose (200 mM) and high-dose (400 mM) treatment with hexapeptide LR6 significantly inhibited TNF-α, IL-1β, and IL-10. The high-dose hexapeptide LR6 showed a better inhibitory effect than the positive control dexamethasone. Hexapeptide LR6 has better anti-inflammatory activity than dexamethasone and can be used to prepare anti-inflammatory drugs.

The present application relates to the field of in vitro cell experiment, in particular to the real simulation of CO2 supply when culturing cells in vitro, and provides a CO2 supply device and method for simulating in vitro CO2 release in vivo. The CO2 supply device for simulating in vitro CO2 release in vivo comprises a membrane device and a CO2 exhaust device; the membrane device is provided with a hydrophobic gas-permeable membrane, one side of the hydrophobic gas-permeable membrane is a gas communication side, the side is provided with a gas chamber, and the other side of the hydrophobic gas-permeable membrane is a liquid contact side; the CO2 exhaust device has an exhaust port for realizing gas suction; the CO2 supply device for simulating in vitro CO2 release in vivo further comprises a gas flow switching unit, the gas flow switching unit comprises three ports respectively leading to the gas chamber, the exhaust port and a CO2 gas source, and a three-way structure is formed between the three ports, and a valve is arranged on the gas flow path corresponding to each port. The present application can solve the problem that the influence of CO2 on cells is not objective and real in the prior art.

The invention is directed to methods and systems for carrying out one or more highly multiplexed cellular assays. In some embodiments, one or more channels of a fluidic device are provided with photopolymerizable polymer precursors and cells randomly disposed on a surface, after which positions of cells are measured by a detector, hydrogel chambers are synthesized by photopolymerization to enclose individual cells, and channels are loaded with assay reagents. Assay signals indicative of desired cellular characteristics can be generated for each of the enclosed cells.

This invention provides an experimental apparatus and method for testing photodamage to retinal pigment epithelial cells. The apparatus comprises an experimental chamber, an experimental platform, a heating mechanism, a light source mechanism, and a photodamage adjustment mechanism. Multiple cell culture dishes are mounted on the experimental platform. The heating mechanism is located below the cell culture dishes within a bottom heating chamber. The light source mechanism includes a light source control head for generating and adjusting the experimental light source, with the control head facing the experimental platform. The photodamage adjustment mechanism is installed on the experimental platform at a position corresponding to the cell culture dishes, and assists in adjusting the experimental light irradiating the cell culture dishes. This invention utilizes the combined operation of the light source mechanism and the photodamage adjustment mechanism to achieve continuous adjustment of the light spot diameter, flexibly simulating photodamage lesions of different scales from microfocal to diffuse, meeting the needs of various disease research.